MedWatch

FDA warns of insulin pump hacking risk

Medtronic’s insulin pump pairs wirelessly with its components – which constitutes a potential cybersecurity risk, the US health authority says. The company has had this problem before.

Photo: Jim Mone/AP/Ritzau Scanpix

In 2019, Medtronic brought a new series of insulin pumps to market – series 600, which comprises models Minimed 630G and Minimed 670G.

The launch was partly driven by the fact that the company’s older devices constituted a cybersecurity risk, according to the US Food and Drug Administration (FDA), which said the pump’s software could be hacked. Medtronic consequently recalled 4,000 units of the Minimed 508 and Minimed Paradigm products.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs